Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous killer T-cell activation via NAP (iTANK)
- Molecular classification
- Cell therapy, Immunotherapy, Gene therapy
01
Overview
The iTANK platform is a gene technology designed to enhance CAR T-cell therapy efficacy, particularly against solid tumors. It arms CAR T-cells with a transgene encoding a neutrophil-activating bacterial protein (NAP). Secreted NAP recruits and activates dendritic cells, leading to the activation of endogenous cytotoxic CD8+ killer T-cells and a broader anti-tumor immune response via epitope spreading.
- Other names
- iTANKCAR(NAP) T-cell therapyEpitope spreading via NAPNAP-mediated T-cell activation
02
Mechanism of action
CAR(NAP) T-cells secrete NAP, recruiting and activating dendritic cells which present tumor-derived neoantigens to activate endogenous cytotoxic CD8+ T cells, leading to epitope spreading and a broader anti-tumor response.
03
Biological functions
T-cell activationDendritic cell recruitmentAntigen presentationEpitope spreadingImmune responseCytotoxicity
04
Disease associations
CancerSolid tumors
05
Safety considerations
Cytokine release syndrome (CRS)NeurotoxicityOff-target toxicityOn-target, off-tumor toxicityImmunogenicity of NAP
06
Interacting drugs
Neutrophil Activating Protein (NAP)
1 more in the full profile.
07
Biomarkers
Tumor-infiltrating lymphocytes (TILs)Neoantigen expressionCAR T-cell persistenceCytokine releaseCD8+ T cell activation markers
Beyond the preview
Go deeper on Endogenous killer T-cell activation via NAP (iTANK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endogenous killer T-cell activation via NAP (iTANK).